Kymera Therapeutics (KYMR) traded higher Monday as investors revisited the company’s late-April catalyst stack: a Q1 2026 business update featuring a $45 million milestone payment triggered when Gilead exercised its option to license Kymera’s KT-200 program, plus an updated liquidity profile showing $1.55 billion in cash, cash equivalents and investments with runway projected into 2029. The combination of non-dilutive collaboration dollars and a long cash runway can support biotech multiples even on modest up days, particularly when the broader tape is risk-on for development-stage names.

Attention is also shifting back toward Kymera’s lead immunology asset KT-621, an oral STAT6 degrader, after the FDA granted Fast Track designation for KT-621 in moderate-to-severe eosinophilic asthma. Kymera has additionally flagged multiple May medical-meeting presentations for KT-621, including late-breaking content emphasizing STAT6 degradation and downstream biology in atopic dermatitis tissue, which can serve as near-term sentiment catalysts even without new pivotal outcomes.

Key upcoming markers for investors include the cadence and content of Kymera’s May KT-621 presentations, any additional partnership or regulatory updates tied to the Gilead KT-200 program following option exercise, and the company’s spending trajectory versus its stated cash runway. Traders will also watch whether the stock’s bounce is accompanied by sustained volume and follow-through as biotech flows rotate back toward immunology and platform-driven stories.